COVID-19 Implications for Biopharma

Jonathan Kfoury

Implications for biopharma

COVID-19 impact on biopharma

reshaping the biopharma ecosystem

ways reshaping the biopharma ecosystem

Biopharma is on front line in combating the crisis

Alliances involving biopharma are being formed

Digital companies are uniquely positioned

M&A to remain active in biopharma

impacting every function in biopharma

closer look at functions

Current challenges with clinical trials

Biopharma supply chain

Commercial/medical functions

Uncertain cash flows and valuations

We encourage biopharma execs

Connect with us

Disclaimer

Related Insights

Organization & Performance

Published Articles

Workers’ desire to work from home grows as lockdown continues

May 22, 2020

New survey shows even more people than in April (now 60%) want to commute less after the COVID crisis, as new working practices become normal.

Organization & Performance

Presentations

Working from Home after COVID

July 21, 2020

COVID-19 is shaping a ‘new normal’ in working from home (WFH) that is expected to persist in the long term. L.E.K. researched how working patterns have…

Life Sciences & Pharma

Executive Insights

Maximizing Oncology Success Through World-Class Guideline and Compendia Strategies

February 18, 2020

National Comprehensive Cancer Network (NCCN) recommendations are considered to be the gold standard for public and private insurers to use in making…

MedTech

Presentations

COVID-19 Impact on Asia-Pacific Hospitals: Edition 3

June 25, 2020

The top concerns for a number of hospitals (~30%) have shifted towards staff wellness, staff capacity and hospital finances due to revenue loss from…

Healthcare Services

Presentations

Election 2020: The Next Phase of the US Healthcare Policy War

October 19, 2020

The results of this study are reflective of news as of October 19, 2020. Overview of key policies and additional details on overall feasibility by…

Life Sciences & Pharma

Executive Insights

After Faltering Start, Japan’s Biosimilars Market Appears on Cusp of Rapid Growth

November 16, 2020

Japan has continued to ensure reasonably favorable pricing and access for innovative drugs, biosimilars have received surprisingly little attention from…